Tokushima, Japan

Takumi Masumoto



 

Average Co-Inventor Count = 22.0

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2011-2018

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Takumi Masumoto: Innovator in Pharmaceutical Chemistry

Introduction

Takumi Masumoto is a notable inventor based in Tokushima, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as monoamines reuptake inhibitors. With a total of 5 patents to his name, Masumoto's work is recognized for its potential therapeutic applications.

Latest Patents

Masumoto's latest patents include innovative N,N-substituted 3-aminopyrrolidine compounds. These compounds are useful as monoamines reuptake inhibitors. The present invention provides a pyrrolidine compound of General Formula (1) or a salt thereof, wherein R and R' are each independently a phenyl group or a pyridyl group. The phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups, which may also be optionally substituted with one or more halogen atoms. The pyrrolidine compound or a salt thereof is usable to produce a pharmaceutical preparation that has a wider therapeutic spectrum and is capable of exhibiting sufficient therapeutic effects after short-term administration.

Career Highlights

Masumoto is currently employed at Otsuka Pharmaceutical Company, Limited, where he continues to advance his research and development efforts. His work focuses on creating innovative solutions that address various health challenges.

Collaborations

Some of his notable coworkers include Muneaki Kurimura and Shinichi Taira, who have collaborated with him on various projects within the pharmaceutical sector.

Conclusion

Takumi Masumoto's contributions to pharmaceutical chemistry through his innovative patents highlight his role as a key inventor in the field. His work continues to pave the way for advancements in therapeutic treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…